Overview

Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.